ScreenerHero

DBV DBV Technologies S.A.

EPA · FR · Healthcare · Biotechnology · dbv-technologies.com
1.856EUR-2.52%Mkt Cap: 633.95M $P/E: —

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherap…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap633.95M USD
Enterprise Value430.68M USD
Revenue (TTM)5.47M USD
Gross Profit5.47M USD
Net Income (TTM)-159.72M USD
Revenue/Share0.02 EUR
Last Price1.856 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees170
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.04
PEG—
EV/EBITDA-2.27
EV/Revenue78.68
P/S118.81
P/B3.96
EPS (TTM)-0.60
EPS (Forward)-0.15
52W Range
1.8161% of range4.500
52W High4.500 EUR
52W Low1.816 EUR
Profitability
Gross Margin100.00%
Oper. Margin-7228.57%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.07%
ROA-62.87%
Growth
Revenue Growth-53.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.72M USD
CapEx (TTM)584.78K USD
FCF Margin-2081.96%
FCF Yield-17.98%
Net Debt-181.74M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.05
Current Ratio3.72
Quick Ratio3.54
Book Value/Sh0.48 EUR
Cash/Share0.59 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.637 EUR
Upside (mean)+95.9%
Target Range1.000 EUR – 5.500 EUR
1.000+95.9% to mean5.500
# Analysts3
Ownership
Shares Out.314.24M
Float174.70M
Insiders0.13%
Institutions51.63%
Technical
SMA 502.302 (-19.4%)
SMA 2003.082 (-39.8%)
Beta-0.23
S&P 52W Chg14.58%
Avg Vol (30d)1.16M
Avg Vol (10d)1.37M
Technical Indicators
RSI (14)31.8
MACD-0.1134
MACD Signal-0.0986
MACD Hist.-0.0148
BB Upper2.363 EUR
BB Middle2.105 EUR
BB Lower1.846 EUR
BB Width24.56%
ATR (14)0.1050 EUR
Vol Ratio (20d)1.04x